Comparative study of drugs approved for prevention of estrogen-responsive breast cancer using molecular docking method

Background and purpose: ERα receptor is one of the most important receptors in response to estrogen hormones, which are highly active in breast cancer. This research aims to investigate the bioinformatic inhibition of this receptor by SERMs, which are selective regulators of estrogen receptors.Materials and methods: This research was carried out using a descriptive-analytical method. The uniprot.org site was used to select the optimal protein and the pubchem.ncbi.nlm.gov site was used to prepare the chemical structure of the desired drugs. Chimera ۱.۱۵ software was also used to prepare the protein for molecular docking. Docking studies were performed by PyRx۰.۸ software.Results: Among all the studied drugs, the best docking results are related to the Bazedoxifene drug. This compound with the most negative binding energy level of -۸.۱ kcal/mol compared to other drugs, has a greater tendency to bind to the ERα receptor